03 July 2018
ConvaTec Group Plc “ConvaTec” or “the Company” has been informed by the CEO of Novo Holdings A/S (“Novo”), Kasim Kutay, of Novo’s desire to effect a rotation in its Board representative. As such, Kasim Kutay will resign his position as a Non-Executive Director of the Company with effect from 3 July 2018.
As a significant investor in ConvaTec, Novo is entitled to nominate one Non-Executive Director to the Board of the Company under the relationship agreement agreed on 31 March 2017 between Novo and ConvaTec. Accordingly, Mr Sten Scheibye will join the Board of ConvaTec on 3 July 2018 as a Non-Executive Director. The appointment of Mr Scheibye has been approved by the Company’s Nominations Committee and the Board.
Sten Scheibye was Chairman of the Novo Nordisk Foundation and of Novo Holdings A/S from 2013 and has recently retired from both these positions. He currently holds the position of Senior Advisor to Novo Holdings. He was appointed Chairman of Healthcare Denmark in 2015. He was a member of the Danish Corporate Governance Committee from 2003 – 2011, serving the last two years as Chairman, and from 1995 – 2008 he was the President and CEO of Coloplast A/S.
Sir Christopher Gent, Chairman of ConvaTec, said:
“I am delighted to welcome Sten to the Board of ConvaTec. He has exceptional experience of the MedTech industry, in addition to a track record of success. We look forward to his contribution”.
Bobby Leach, VP Group Corporate Affairs, ConvaTec
+44 (0)7770 842 226
Alastair Elwen, Finsbury
+44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, ConvaTec
+44 (0)7500 141 435
Kirsty Law, Director Investor Relations, ConvaTec
+44 (0)7470 909 582
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec’s products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.